AdvanSix: Q2 Misses Are Real. The 44% Discount to Book Value Is the Bigger Story.

AdvanSix shares dropped nearly 19% on August 7 after the company reported adjusted diluted earnings of $0.19 per share for the second quarter of 2026 — far below the $0.61 analysts expected and a sharp decline from $1.24 a year earlier. Revenue of $421.3 million came in above prior year but $25 million short of consensus. Adjusted EBITDA collapsed 43% to $31.9 million.

The headline is ugly. The underlying story is different. The market is pricing a distressed business. The data says this is a cyclical trough for a low-cost integrated chemical manufacturer trading at 0.55 times book value — about $16.44 per share against a book value of roughly $29.50. That is not the mark of a company going broke. That is the mark of a market that hates cyclical names in a downturn.

Let me start with what happened.

The volume problem

Volumes fell 15% year over year, contributing a $17 million negative impact to EBITDA. The Plant Nutrients segment — ammonium sulfate fertilizer — was the biggest drag, with sales down 16% to $131.4 million as softer farmer economics reduced in-season purchases. The Chemical Intermediates segment actually rose 18% to $127.0 million, and Nylon grew 26% to $100.2 million despite a soft caprolactam market. So the decline wasn't across the board — it was concentrated in fertilizer timing.

The cost wall

Raw material costs rose $72 million year over year, driven by record-high sulfur prices ($705 per long ton in the third quarter of 2026) and higher benzene and propylene costs. Every $100 per ton change in sulfur translates to roughly $35 million in annual cost impact for AdvanSix. That is a massive input exposure. But management stated that pricing actions — a 13% raw-material pass-through and a 5% market-based pricing increase — fully offset that $72 million headwind. Net price over raw materials came in flat for the quarter, a marked improvement from the first quarter's net-negative result.

Then there was the ammonia plant turnaround, moved into Q2 to align with a supplier's natural gas pipeline inspection. The Hopewell facility ran at mid-70% utilization, constraining ammonia production and limiting downstream product flexibility. That added another $4 million in unfavorable impact. These are operational timing issues, not structural failures.

From a cash-flow perspective, the quarter was thin but not alarming. Operating cash flow came in at $10.0 million, down 52% from a year ago. Free cash flow was negative $10.7 million, with capital expenditures of $20.7 million exceeding cash generation. The revolver balance on the $500 million credit facility rose to $275 million from $215 million, and cash on the balance sheet fell to $7.2 million. That looks uncomfortable until you note two things: capex for 2026 is guided at $75 million to $95 million, a substantial decline from $116.4 million in 2025; and management expects second-half cash flow to improve from lower capex, a Q4 fertilizer pre-buy working capital tailwind, and cash receipts from 45Q carbon capture tax credits.

The 45Q credits are worth examining separately. AdvanSix's Hopewell facility captures CO2 from its ammonia production and converts it into urea, qualifying for Section 45Q tax credits designed to incentivize carbon sequestration. The company targets $100 million to $125 million in these credits, has $18 million already accrued on its balance sheet awaiting IRS audit resolution, and expects cash receipt in the second half of 2026. That is a real cash inflow — not accounting sugar.

Now let's talk about valuation, because this is where the market has overreacted.

At a market cap of roughly $442 million and an enterprise value of about $694 million, AdvanSix trades at 0.55 times book value, 0.29 times trailing sales, and 9.2 times trailing EV/EBITDA. To put that in context, Eastman Chemical — a diversified peer in the specialty chemicals space — trades at 10.7 times EV/EBITDA and 1.38 times book value. LyondellBasell, a larger integrated player, sits at 12.5 times EV/EBITDA. AdvanSix is trading at a steep discount to peers despite having what has historically been a stronger margin profile when the cycle is not at its trough.

For full year 2025, AdvanSix generated $156.8 million in adjusted EBITDA on a 10.3% margin, up from $142.1 million at 9.4% the prior year. Operating cash flow was $122.9 million. The business was producing. It was covering its dividend of $0.64 per share. The trailing twelve-month dividend yield is now roughly 3.9%, but the payout ratio has ballooned to 165% of earnings on a TTM basis because Q1 and Q2 2026 were losses. That dividend risk is real. I will address it below.

The structural moat remains intact

AdvanSix's competitive position hasn't changed because sulfur prices are high. The company is the global low-cost producer of caprolactam, an essential nylon building block. Approximately 90% of its sales occur in the United States, insulating it from the reciprocal tariff pressures weighing on many diversified chemical peers. Anti-dumping duties on imported acetone — a Chemical Intermediates product — were renewed for five years, structurally tightening U.S. supply and expanding acetone-propylene spreads from $0.10 per pound to a sustainable $0.15 to $0.20 range. That spread improvement alone should add roughly $30 million annually to mid-cycle EBITDA.

The granular ammonium sulfate program — transitioning fertilizer into a slower-release, higher-value form that commands a $75-per-ton premium — is nearly complete after consuming most growth capex in recent years. That program should add more than $15 million annually to mid-cycle adjusted EBITDA. With capex guidance for 2026 set well below 2025 spending, the heavy investment phase is ending. Free cash flow should respond.

The nylon market is in a cyclical trough, no question. Chinese capacity expansion and weak automotive and textile demand have kept prices depressed since 2023. But industry capacity rationalization and lower operating rates are emerging, and long-term nylon 6 and caprolactam demand is expected to grow at a mid-single-digit rate through the early 2030s. AdvanSix's low-cost position means it survives troughs that force high-cost producers offline.

The risks

While it's true that the valuation discount is wide, I would argue that three risks deserve serious attention before buying.

First, the dividend. At 165% of trailing earnings, the $0.64 per share annual payout is not currently covered by profits. If Q3 also disappoints — and management has guided for a $10 million to $15 million year-over-year headwind driven by the fertilizer seasonal reset and persistent high sulfur costs — the board may need to cut or suspend the dividend. That would remove part of the current yield-based support for the stock.

Second, sulfur costs are not guaranteed to fall soon. Management noted that industry experts forecast a roughly $200 per ton decline entering 2027, but Q3 and Q4 2026 could remain elevated. At $705 per long ton, the cost burden is severe.

Third, the credit facility. Total debt stands at approximately $914 million per trailing data, though the Q2 report shows a revolver draw of $275 million against a $500 million facility with a maturity extended to October 2027. The debt-to-equity ratio of roughly 34% is manageable, and the company has $225 million of undrawn revolver capacity. But with cash at $7.2 million and negative free cash flow for the quarter, the revolver is doing real work. That creates refinancing risk if credit conditions tighten before the cycle recovers.

Even if the dividend is cut, even if sulfur stays expensive through year-end, the thesis that AdvanSix is trading far below its normalized earnings power still holds. A mid-cycle adjusted EBITDA of roughly $180 million to $200 million — which would reflect the return of acetone spreads, completion of the granular ammonium sulfate transition, normalized volumes, and the tailwind from 45Q credits — would imply an EV/EBITDA of 3.5x to 3.8x at current levels. That is a deep value zone even by chemical industry standards, where trough multiples of 6x to 8x are common.

All things considered, the Q2 miss was painful but explained: a volume timing hit in fertilizer, record sulfur costs, and a plant turnaround that compressed utilization. None of these are permanent. The business model — vertically integrated, U.S.-centric, structurally protected by anti-dumping duties, sitting at the low-cost end of the caprolactam curve — is unchanged. The balance sheet, while stretched by the current downturn, has adequate facility headroom and no imminent covenant breach risk.

I acknowledge the dividend risk openly. If earnings stay depressed through Q3, a cut is possible. But a dividend cut is a risk to income investors, not a death sentence for the equity. At 0.55 times book value, the market has already priced in significant deterioration.

I reaffirm my Strong Buy rating. The margin of safety at these levels is substantial, the cyclical tailwinds for 2027 are stacking, and the peer discount still implies meaningful re-rating potential if the balance sheet holds. This is the kind of crack between headline panic and underlying data that the patient value investor looks for.